<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7019229/results/search/drug/results.xml">
  <result pre="trials. Seven anti-HCMV drugs have received approval for various indications:" exact="Ganciclovir" post="(GCV), Valganciclovir, Acyclovir, Foscarnet, Cidofovir, Letermovir and Fomivirsen [60,61,62,63]."/>
  <result pre="for the prevention and treatment of HCMV disease. The prodrug" exact="Valganciclovir" post="is an orally applicable valine ester that is rapidly"/>
  <result pre="very modest antiviral activity for HCMV [60,65]. Thus, GCV and" exact="Valganciclovir" post="have been the first line choice for prevention and"/>
  <result pre="either pUL97 or pUL54 [67,68]. In such cases, Foscarnet or" exact="Cidofovir" post="are the usual alternative treatments. The two drugs do"/>
  <result pre="nucleotide triphosphate substrate during incorporation into the nascent DNA chain." exact="Cidofovir" post="is an acyclic nucleoside phosphonate and an analogue of"/>
  <result pre="by pUL54 inhibits viral genome replication. Resistance to Foscarnet and" exact="Cidofovir" post="occurs with rates similar to GCV, and the two"/>
  <result pre="clinical use [66,67]. Brincidofovir is a lipid ester prodrug of" exact="cidofovir" post="with improved oral bioavailability and reduced toxicity that demonstrated"/>
  <result pre="transcriptional repression as a whole, constituents of these organelles including" exact="alpha" post="thalassemia/mental retardation syndrome X-linked protein (ATRX), death domain-associated protein"/>
  <result pre="particular, epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor" exact="alpha" post="and integrins independently trigger the phosphatidylinositol 3-phosphate and protein"/>
  <result pre="be involved in the IE phase of HCMV infection include" exact="adenosine" post="monophosphate-activated protein kinase (AMPK) [173], hematopoietic cell kinase (a"/>
  <result pre="have not had their mechanism of action fully elucidated. 6.2." exact="Artemisinin" post="and Derivatives Testing compounds that have anecdotal evidence suggesting"/>
  <result pre="the anti-HCMV activity of natural product artemisinin, its semi-synthetic derivative" exact="artesunate" post="and various related compounds. Artemisinin is a natural product"/>
  <result pre="product artemisinin, its semi-synthetic derivative artesunate and various related compounds." exact="Artemisinin" post="is a natural product derived from the plant Artemisia"/>
  <result pre="(Sweet Wormwood), a herb used in traditional Chinese medicine [317,318]." exact="Artemisinin" post="and its derivatives are best known for effective antimalarial"/>
  <result pre="activity and treatment [317,318], which provided the premise for testing" exact="artesunate" post="for anti-HCMV activity [319]. Artesunate, along with various related"/>
  <result pre="potent, selective HCMV inhibitor with irreversible activity [332,333] and trimeric" exact="artesunate" post="derivative TF27 [326], which exhibits potent in vitro and"/>
  <result pre="compounds and GCV [334,335,336,337]. The mechanism of action by which" exact="artesunate" post="and the various derivatives generate their anti-HCMV activity has"/>
  <result pre="not been fully elucidated, but the general consensus is that" exact="artesunate" post="primarily interferes with the NF-κΒ pathway [319,326,331]. The NF-κΒ"/>
  <result pre="of the compound with NF-κΒ subunit RelA/p65 [319,326,331]. Interaction of" exact="artesunate" post="with a host cell factor leads to the expectation"/>
  <result pre="drug resistance would be less likely; indeed, attempts to generate" exact="artesunate" post="drug-resistant isolates in vitro have thus far been unsuccessful"/>
  <result pre="modulation of cell cycle progression, have also been proposed for" exact="artesunate" post="compounds [319,340]. Clinical use of artesunate for management of"/>
  <result pre="also been proposed for artesunate compounds [319,340]. Clinical use of" exact="artesunate" post="for management of drug-resistant HCMV infections in stem cell"/>
  <result pre="study [341] and the long and safe clinical history of" exact="artesunate" post="treatment in malaria patients [317]. The first use of"/>
  <result pre="artesunate treatment in malaria patients [317]. The first use of" exact="artesunate" post="in a clinical setting was a success with artesunate"/>
  <result pre="of artesunate in a clinical setting was a success with" exact="artesunate" post="being reported as an effective inhibitor of HCMV replication"/>
  <result pre="[342]. However, subsequent studies reported either mixed success or that" exact="artesunate" post="was ineffective in controlling HCMV infection [343,344,345]. Further studies"/>
  <result pre="clinical outcomes for artesunate-treated patients, and studies with more potent" exact="artesunate" post="derivatives may hold future promise. For example, the trimeric"/>
  <result pre="for anti-HCMV testing is the multi-targeted anti-cancer tyrosine kinase inhibitor" exact="sorafenib" post="(Nexavar), which has been shown to inhibit MIEP activity,"/>
  <result pre="later stages of HCMV replication [172]. The mechanism by which" exact="sorafenib" post="inhibits HCMV was not fully elucidated due to its"/>
  <result pre="to modulate cell signalling pathways [370]. For example, cardiac glycoside" exact="digitoxin" post="has been reported to inhibit HCMV through induction of"/>
  <result pre="vivo testing using the MCMV model, and clinical testing of" exact="artesunate" post="produced mixed clinical outcomes that warrant further investigation. Overall,"/>
  <result pre="are deguelin (DGN), nitazoxanide (NTZ), thioguanosine (TGN), alexidine dihydrochloride (AXN)," exact="manidipine" post="dihydrochloride (MND) and berberine (BBR). All hits inhibited HCMV"/>
  <result pre="Med. Virol.20102020221310.1002/rmv.65520564615 36.GaneE.SalibaF.ValdecasasG.J.O’GradyJ.PescovitzM.D.LymanS.RobinsonC.A.Randomised trial of efficacy and safety of oral" exact="ganciclovir" post="in the prevention of cytomegalovirus disease in liver-transplant recipients."/>
  <result pre="the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral" exact="Ganciclovir" post="International Transplantation Study Group [corrected]Lancet19973501729173310.1016/S0140-6736(97)05535-99413463 37.LowanceD.NeumayerH.H.LegendreC.M.SquiffletJ.P.KovarikJ.BrennanP.J.NormanD.MendezR.KeatingM.R.CoggonG.L.et al.Valacyclovir for the"/>
  <result pre="for the prevention of cytomegalovirus disease after renal transplantation. International" exact="Valacyclovir" post="Cytomegalovirus Prophylaxis Transplantation Study GroupN. Engl. J. Med.19993401462147010.1056/NEJM19990513340190310320384 38.WreghittT.G.AbelS.J.McNeilK.ParameshwarJ.StewartS.CaryN.SharplesL.LargeS.WallworkJ.Intravenous"/>
  <result pre="Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study GroupN. Engl. J. Med.19993401462147010.1056/NEJM19990513340190310320384 38.WreghittT.G.AbelS.J.McNeilK.ParameshwarJ.StewartS.CaryN.SharplesL.LargeS.WallworkJ.Intravenous" exact="ganciclovir" post="prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant"/>
  <result pre="mitogenicityCancer Res.20086872473010.1158/0008-5472.CAN-07-229118245472 159.KudchodkarS.B.YuY.MaguireT.G.AlwineJ.C.Human cytomegalovirus infection alters the substrate specificities and" exact="rapamycin" post="sensitivities of raptor- and rictor-containing complexesProc. Natl. Acad. Sci."/>
  <result pre="infected cellsProc. Natl. Acad. Sci. USA201210958859310.1073/pnas.111496610822203987 172.MichaelisM.PaulusC.LoschmannN.DauthS.StangeE.DoerrH.W.NevelsM.CinatlJ.Jr.The multi-targeted kinase inhibitor" exact="sorafenib" post="inhibits human cytomegalovirus replicationCell. Mol. Life Sci.2011681079109010.1007/s00018-010-0510-820803231 173.MukhopadhyayR.VenkatadriR.KatsnelsonJ.Arav-BogerR.Digitoxin suppresses"/>
  <result pre="of human cytomegalovirus replication by union of the major enhancer" exact="retinoic acid," post="cyclic AMP, and NF-κB response elementsJ. Virol.201589122841229810.1128/JVI.00965-1526423948 177.KowalikT.F.WingB.HaskillJ.S.AzizkhanJ.C.BaldwinA.S.Jr.HuangE.S.Multiple mechanisms"/>
  <result pre="silencing and genome editingCurr. Opin. Virol.201724465410.1016/j.coviro.2017.04.00128437703 317.EfferthT.RomeroM.R.WolfD.G.StammingerT.MarinJ.J.MarschallM.The antiviral activities of" exact="artemisinin" post="and artesunateClin. Infect. Dis.20084780481110.1086/59119518699744 318.HoW.E.PehH.Y.ChanT.K.WongW.S.Artemisinins: Pharmacological actions beyond anti-malarialPharmacol."/>
  <result pre="Dis.20084780481110.1086/59119518699744 318.HoW.E.PehH.Y.ChanT.K.WongW.S.Artemisinins: Pharmacological actions beyond anti-malarialPharmacol. Ther.201414212613910.1016/j.pharmthera.2013.12.00124316259 319.EfferthT.MarschallM.WangX.HuongS.M.HauberI.OlbrichA.KronschnablM.StammingerT.HuangE.S.Antiviral activity of" exact="artesunate" post="towards wild-type, recombinant, and ganciclovir-resistant human cytomegalovirusesJ. Mol. Med.20028023324210.1007/s00109-001-0300-811976732"/>
  <result pre="Med.20028023324210.1007/s00109-001-0300-811976732 320.Arav-BogerR.HeR.ChiouC.J.LiuJ.WoodardL.RosenthalA.Jones-BrandoL.FormanM.PosnerG.Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to" exact="artemisinin" post="monomersPLoS ONE20105e1037010.1371/journal.pone.001037020442781 321.ChouS.MarousekG.AuerochsS.StammingerT.MilbradtJ.MarschallM.The unique antiviral activity of artesunate is"/>
  <result pre="compared to artemisinin monomersPLoS ONE20105e1037010.1371/journal.pone.001037020442781 321.ChouS.MarousekG.AuerochsS.StammingerT.MilbradtJ.MarschallM.The unique antiviral activity of" exact="artesunate" post="is broadly effective against human cytomegaloviruses including therapy-resistant mutantsAntivir."/>
  <result pre="against human cytomegaloviruses including therapy-resistant mutantsAntivir. Res.20119236436810.1016/j.antiviral.2011.07.01821843554 322.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of" exact="ganciclovir" post="and artesunate towards human cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209"/>
  <result pre="cytomegaloviruses including therapy-resistant mutantsAntivir. Res.20119236436810.1016/j.antiviral.2011.07.01821843554 322.SchnepfN.CorvoJ.PorsM.J.MazeronM.C.Antiviral activity of ganciclovir and" exact="artesunate" post="towards human cytomegalovirus in astrocytoma cellsAntivir. Res.20118918618810.1016/j.antiviral.2010.12.00221167209 323.MorereL.AndouardD.LabrousseF.SaadeF.CallisteC.A.CotinS.AubardY.RawlinsonW.D.EsclaireF.HantzS.et al.Ex"/>
  <result pre="antimalarial, antileukemia and antiviral activitiesBioorg. Med. Chem.2015235452545810.1016/j.bmc.2015.07.04826260339 325.ReiterC.FröhlichT.ZeinoM.MarschallM.BahsiH.LeidenbergerM.FriedrichO.KappesB.HampelF.EfferthT.et al.New efficient" exact="artemisinin" post="derived agents against human leukemia cells, human cytomegalovirus and"/>
  <result pre="1,2,4-trioxane-ferrocene hybridsEur. J. Med. Chem.20159716417210.1016/j.ejmech.2015.04.05325965779 326.HuttererC.NiemannI.MilbradtJ.FröhlichT.ReiterC.KadiogluO.BahsiH.ZeittragerI.WagnerS.EinsiedelJ.et al.The broad-spectrum antiinfective drug" exact="artesunate" post="interferes with the canonical nuclear factor kappa B (NF-κB)"/>
  <result pre="synergism with several antiviral agents against human cytomegalovirusAntivir. Ther.20162153553910.3851/IMP302826844400 328.Oiknine-DjianE.WeisblumY.PanetA.WongH.N.HaynesR.K.WolfD.G.The" exact="artemisinin" post="derivative artemisone is a potent inhibitor of human cytomegalovirus"/>
  <result pre="reactionsNat. Commun.201781507110.1038/ncomms1507128462939 335.FröhlichT.ReiterC.IbrahimM.M.BeutelJ.HuttererC.ZeittragerI.BahsiH.LeidenbergerM.FriedrichO.KappesB.et al.Synthesis of novel hybrids of quinazoline and" exact="artemisinin" post="with high activities against plasmodium falciparum, human cytomegalovirus, and"/>
  <result pre="mediated through cell cycle modulationAntimicrob. Agents Chemother.2015593870387910.1128/AAC.00262-1525870074 341.KapteinS.J.EfferthT.LeisM.RechterS.AuerochsS.KalmerM.BruggemanC.A.VinkC.StammingerT.MarschallM.The anti-malaria drug" exact="artesunate" post="inhibits replication of cytomegalovirus in vitro and in vivoAntivir."/>
  <result pre="transplantationClin. Infect. Dis.2008461455145710.1086/58710618419454 343.WolfD.G.ShimoniA.ResnickI.B.StammingerT.NeumannA.U.ChouS.EfferthT.CaplanO.RoseJ.NaglerA.et al.Human cytomegalovirus kinetics following institution of" exact="artesunate" post="after hematopoietic stem cell transplantationAntivir. Res.20119018318610.1016/j.antiviral.2011.03.18421443904 344.LauP.K.WoodsM.L.RatanjeeS.K.JohnG.T.Artesunate is ineffective"/>
  <result pre="valganciclovir-resistant cytomegalovirus infectionClin. Infect. Dis.20115227910.1093/cid/ciq05021288859 345.GermiR.MarietteC.AlainS.LupoJ.ThiebautA.BrionJ.P.EpaulardO.Saint RaymondC.MalvezziP.MorandP.Success and failure of" exact="artesunate" post="treatment in five transplant recipients with disease caused by"/>
  <result pre="protein activityJ. Appl. Microbiol.20081051791180110.1111/j.1365-2672.2008.03927.x19120629 381.MercorelliB.LuganiniA.CelegatoM.PaluG.GribaudoG.LoregianA.Repurposing the clinically approved calcium antagonist" exact="manidipine" post="dihydrochloride as a new early inhibitor of human cytomegalovirus"/>
  <result pre="duodenal homeobox 1 protein; PPARG, peroxisome proliferator-activated receptor gamma; RARA," exact="retinoic acid" post="receptor alpha; RBBP4, Rb binding protein 4 chromatin remodelling"/>
  <result pre="DGN, deguelin; NZT, nitazoxanide; TGN, thioguanosine; AXN, alexidine dihydrochloride; MND," exact="manidipine" post="dihydrochloride."/>
 </snippets>
</snippetsTree>
